Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

BACKGROUND: Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG)....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Lee, Eudocia Q., Reardon, David A., Schiff, David, Drappatz, Jan, Muzikansky, Alona, Grimm, Sean A., Norden, Andrew D., Nayak, Lakshmi, Beroukhim, Rameen, Rinne, Mikael L., Chi, Andrew S., Batchelor, Tracy T., Hempfling, Kelly, McCluskey, Christine, Smith, Katrina H., Gaffey, Sarah C., Wrigley, Brendan, Ligon, Keith L., Raizer, Jeffrey J., Wen, Patrick Y.
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2015
Предметы:
Clinical Investigations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4483124/
https://ncbi.nlm.nih.gov/pubmed/25572329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou350
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы